Archives

  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • Brefeldin A (BFA): ATPase and Vesicle Transport Inhibitor...

    2025-10-26

    Brefeldin A (BFA): ATPase and Vesicle Transport Inhibitor in ER Stress Research

    Executive Summary: Brefeldin A (BFA, CAS 20350-15-6) is a small-molecule ATPase inhibitor with an IC50 of ~0.2 μM, disrupting ER-to-Golgi protein trafficking and inducing ER stress (ApexBio). It is widely used to study vesicle transport, ER stress, and apoptosis in cancer cell models such as MCF-7, HCT116, and HeLa (Chen et al., 2021). BFA is insoluble in water but dissolves in DMSO and ethanol, supporting flexible experimental workflows. Its actions model ER stress pathways and caspase-mediated apoptosis, key to cancer and vascular injury research (ATPsolution, 2023). BFA’s utility is benchmarked by reproducible induction of ER swelling, Golgi disruption, and protein secretion blockade.

    Biological Rationale

    Brefeldin A (BFA) is derived from Eupenicillium brefeldianum and characterized as a potent modulator of intracellular trafficking. It specifically blocks protein transport from the endoplasmic reticulum (ER) to the Golgi apparatus by inhibiting guanine nucleotide exchange on ARF GTPases (ApexBio). The disruption of vesicle transport impairs secretion, induces ER stress, and affects cell viability. This makes BFA an essential probe for dissecting ER-associated degradation, unfolded protein response, and apoptosis—critical in cancer, immunology, and vascular biology (ER-mScarlet). In cancer models, BFA’s induction of ER stress and p53 expression is leveraged to study apoptosis and tumor cell susceptibility to stress-induced death (Chen et al., 2021).

    Mechanism of Action of Brefeldin A (BFA)

    BFA inhibits ATPase activity at an IC50 of ~0.2 μM, impacting ARF GTPases and thus blocking the exchange of GDP for GTP on ARF1 (ApexBio). This prevents the assembly of COPI coats on Golgi membranes, resulting in the collapse of the Golgi into the ER. The consequence is a rapid blockade of protein trafficking from the ER to Golgi and subsequent suppression of vesicular exocytosis. In cellular models, this leads to ER swelling, disassembly of the Golgi apparatus, and cytoskeletal disruption (Golgi-mTurquoise2). BFA also induces ER stress, activating the unfolded protein response (UPR) and downstream apoptotic pathways, including p53 upregulation in tumor cell lines such as HCT116 (colorectal), HeLa (cervical), and MCF-7 (breast).

    Evidence & Benchmarks

    • BFA inhibits ATPase activity with an IC50 of 0.2 μM in vitro (ApexBio, product page).
    • BFA blocks ER-to-Golgi protein trafficking by inhibiting ARF GTPase-mediated COPI coat formation (ATPsolution, 2023).
    • BFA induces ER stress, p53 expression, and apoptosis in colorectal (HCT116), breast (MCF-7, MDA-MB-231), and cervical (HeLa) cancer cell lines (Chen et al., 2021).
    • BFA reduces clonogenicity and migration in MDA-MB-231 breast cancer cells (ER-mScarlet, 2023).
    • BFA-induced ER stress models are used to validate biomarker discovery in vascular injury and sepsis research (Chen et al., 2021).
    • BFA is insoluble in water but soluble in ethanol (≥11.73 mg/mL, with ultrasonic treatment) and DMSO (≥4.67 mg/mL); solutions require storage below -20°C (ApexBio, product page).

    Applications, Limits & Misconceptions

    BFA is a gold standard for dissecting vesicular transport, ER stress, and apoptosis. It is used to:

    • Induce ER swelling and peripheral Golgi localization in normal rat kidney cells.
    • Disrupt cytoskeletal organization and Golgi integrity in various mammalian cell lines.
    • Inhibit clonogenic and migratory activity of breast cancer cells (MDA-MB-231) via caspase and p53 pathways.
    • Downregulate cancer stem cell markers and anti-apoptotic proteins, promoting apoptosis in colorectal and breast cancer models (Chen et al., 2021).
    • Serve as a tool in vascular biology studies of endothelial injury and permeability—complementary to sepsis biomarker research.

    BFA’s robust action enables reproducible modeling of ER stress and vesicle trafficking, providing a foundation for translational research in oncology, cell biology, and vascular pathophysiology (NSC23766.com). This article extends prior analyses by detailing BFA's benchmarks and decision points for workflow integration, especially for cancer and ER stress researchers.

    Common Pitfalls or Misconceptions

    • BFA is not effective in water-based solutions due to insolubility; use DMSO or ethanol for stock solutions (ApexBio).
    • BFA is not a universal apoptosis inducer; its effect is context-dependent and may not trigger apoptosis in all cell types or under all conditions.
    • Long-term stock solutions are unstable; BFA should be prepared fresh or stored below -20°C and not used after multiple freeze-thaw cycles.
    • BFA does not inhibit all forms of vesicular trafficking; its primary action is on ER-to-Golgi transport, not on all secretory pathways.
    • BFA use does not directly measure endpoint functional outcomes; additional assays are required to assess ER stress or apoptosis induction.

    Workflow Integration & Parameters

    BFA is supplied as B1400 (CAS 20350-15-6), with recommended dissolution in DMSO (≥4.67 mg/mL) or ethanol (≥11.73 mg/mL, with ultrasonic treatment). For higher concentrations, warming to 37°C and ultrasonic shaking are suggested. Stock solutions must be stored below -20°C and used promptly. In ER stress and apoptosis assays, BFA concentrations typically range from 0.1 to 5 μM, with exposure times from 30 minutes to 24 hours depending on cell type and endpoint.

    Integrate BFA with immunofluorescence, Western blotting, or functional cell viability assays to monitor ER stress markers, Golgi morphology, and apoptosis (see ATPsolution article for advanced workflow guidance—this article details recent evidence and application-specific decision points). BFA’s reproducibility supports high-content screening and mechanistic studies in both basic and translational contexts.

    Conclusion & Outlook

    Brefeldin A (BFA) is an established ATPase and vesicle transport inhibitor, critical for modeling ER stress, protein trafficking, and apoptosis. Its validated benchmarks and robust solubility protocols make it a preferred reagent in cancer and vascular injury research. Future directions include leveraging BFA-induced ER stress for biomarker validation in sepsis and precision oncology. For comprehensive product details and validated protocols, consult the Brefeldin A (BFA) product page.